Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Evotec Ag Ads (EVTCY)

Evotec Ag Ads (EVTCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,398,568
  • Shares Outstanding, K 74,530
  • Annual Sales, $ 443,350 K
  • Annual Income, $ 99,410 K
  • 60-Month Beta 1.28
  • Price/Sales 7.27
  • Price/Cash Flow 25.04
  • Price/Book 6.68
  • Price/Earnings ttm 46.83
  • Earnings Per Share ttm 0.98
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.34
  • Growth Rate Est. (year over year) +293,723.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.6800 +12.09%
on 08/20/19
46.0000 -0.87%
on 09/16/19
+3.6500 (+8.70%)
since 08/16/19
3-Month
40.6800 +12.09%
on 08/20/19
59.5000 -23.36%
on 07/29/19
-5.1000 (-10.06%)
since 06/12/19
52-Week
35.5700 +28.20%
on 10/10/18
59.5000 -23.36%
on 07/29/19
-5.5200 (-10.80%)
since 09/17/18

Most Recent Stories

More News
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

LJPC : 10.16 (-1.17%)
ASRT : 1.38 (+4.55%)
SLNO : 1.85 (+7.56%)
EVTCY : 45.6000 (-0.63%)
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment

Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.

ACER : 3.62 (+4.32%)
CPIX : 5.38 (+1.70%)
EVTCY : 45.6000 (-0.63%)
NEOS : 1.70 (-1.73%)
Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse

Catalyst Pharma (CPRX) gains on the successful launch of Firdapse. The company is looking to develop drug for additional indications.

CPRX : 6.62 (+0.76%)
REPH : 11.84 (+0.77%)
EVTCY : 45.6000 (-0.63%)
NEVPF : 0.2020 (+6.32%)
Catalent Acquires Gene Therapy Leader Paragon Bioservices

Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

ESALY : 50.4200 (+0.28%)
CTLT : 51.60 (+1.90%)
REPH : 11.84 (+0.77%)
EVTCY : 45.6000 (-0.63%)
Evotec Completes Repayment Of EUR 140 M Acquisition Loan

EUR 140 M BRIDGE LOAN WAS DRAWN TO SECURE EVOTEC'S VALUE CHAIN EXPANSION BY SUCCESSFUL ACQUISITION OF APTUIT IN AUGUST 2017 STRONG OPERATIONAL CASH FLOW ENABLES FULL REPAYMENT WITHIN LESS THAN TWO YEARS...

EVTCY : 45.6000 (-0.63%)
Evotec to Attend Upcoming Investor Conferences

HAMBURG, GERMANY / ACCESSWIRE / March 7, 2019 / Evotec AG (FSE: EVT, OTC PINK: EVTCY, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following...

EVTCY : 45.6000 (-0.63%)
Evotec Receives Milestone Payment for Start of Phase II Clinical Trial

EVOTEC'S PARTNER, SECOND GENOME, BEGINS A PHASE II CLINICAL TRIAL FOR NASH WITH LICENSED MOLECULE, SGM-1019

EVTCY : 45.6000 (-0.63%)
Evotec Reaches Important Scientific Achievement Within IPSC-Based Collaboration With Celgene

FIRST PROGRAMME ADVANCED INTO LEAD OPTIMISATION CELGENE DESIGNATES PROGRAMME AND TRIGGERS PAYMENT OF $ 14.0 M TO EVOTEC

EVT : 24.53 (-0.28%)
CELGZ : 0.57 (+3.62%)
EVTCY : 45.6000 (-0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade EVTCY with:

Key Turning Points

2nd Resistance Point 45.6667
1st Resistance Point 45.6333
Last Price 45.6000
1st Support Level 45.5833
2nd Support Level 45.5667

See More

52-Week High 59.5000
Fibonacci 61.8% 50.3587
Fibonacci 50% 47.5350
Last Price 45.6000
Fibonacci 38.2% 44.7113
52-Week Low 35.5700

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar